SGLT2-I cardiovascular outcome trials in diabetes mellitus patients demonstrated that empagliflozin, canagliflozin, and dapagliflozin reduce hyperfiltration at the onset of therapy and slow the decline in estimated glomerular filtration rate (eGFR) in the long-term. This evidence concerns the gene SLC5A2 and diabetes mellitus.